米氮平治疗伴有睡眠障碍的围绝经期综合征患者的疗效分析

目的分析米氮平治疗伴有睡眠障碍的围绝经期综合征患者的临床疗效。方法选取2017年1月~2019年5月内收治的伴有睡眠障碍的围绝经期综合征患者60例,随机法分为2组,各30例。对照组采用谷维素片治疗,试验组采用米氮平治疗。比较两组治疗前、后4w、8w时汉密尔顿抑郁量表(HAMD)、匹兹堡睡眠指数(PSQI)等评分变化、总体疗效及不良反应。结果治疗前两组各项评分无明显差异(P>0.05),治疗4w、8w后,实验组HAMD、PSQI等评分改善明显优于对照组(P<0.05)。试验组总有效率更高(P<0.05),对照组的不良反应率低于试验组(P<0.05)。结论米氮平治疗伴有睡眠障碍的围绝经期综合征患者的效果较为确切,可明显改善患者睡眠质量和抑郁症状,但存在一些不良反应。

The effect of mirtazapine in the treatment of patients with perimenopausal syndrome and sleep disorders

Objective To analyze the clinical effect of mirtazapine on patients with perimenopausal syndrome and sleep disorder.Methods From January 2017 to May 2019,60 patients with perimenopausal syndrome and sleep disorders were selected and randomly divided into two groups,30 in each group.The control group was treated with oryzanol and the experimental group was treated with mirtazapine.The changes of HAMD and PSQI scores,the overall efficacy and adverse reactions were compared between the two groups before and after 4 and 8 weeks of treatment.Results The scores of HAMD and PSQI in the experimental groups were better than those in the control group(P<0.05).The total effective rate of the experimental groups was better than that of the control group(P<0.05).The adverse reaction rate of the control groups was better than that of the experimental group(P<0.05).Conclusion The effect of mirtazapine in the treatment of patients with perimenopausal syndrome and sleep disorders is good,which can significantly improve the sleep quality and depression of patients,but there are some adverse reactions.